Johnson & Johnson, which did not apply for the national priority voucher, was granted the ticket based on results from a Phase III study testing Tecvayli plus Darzalex in patients with relapsed or ...
Today, a brief rundown of news from Johnson & Johnson and Pfizer, as well as updates from Gilead Sciences, Link Cell Therapies and Sanofi that you may have missed. AbbVie reached legal settlements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback